New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
11:35 EDTRHHBY, HALOHalozyme announces positive CHMP opinion on Roche's MabThera SC
Halozyme Therapeutics (HALO) announced that the EU Committee for Medicinal Products for Human Use, or CHMP, has recommended that the European Commission approve Roche's (RHHBY) subcutaneous formulation of MabThera using Halozyme's recombinant human hyaluronidase for the treatment of patients with common forms of non-Hodgkin lymphoma. The CHMP opinion is based primarily on data from Roche's Phase 3 SABRINA study. Roche expects a final decision from the European Commission in the coming months, Halozyme said. In 2006, Halozyme entered into an agreement with Roche and to date, Roche has elected to explore the use of rHuPH20 for up to a total of five exclusive targets, and Roche retains the option to apply rHuPH20 to three additional targets through the payment of annual license maintenance fees. Subject to the successful achievement of clinical, regulatory, and sales events, Roche will pay Halozyme additional milestones as well as royalties on product sales for Herceptin SC, MabThera SC and any other product candidates which would be successfully developed and commercialized under the agreement.
News For HALO;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 27, 2015
07:51 EDTRHHBYRoche catching up fast to Bristol-Myers in immuno-oncology, says Jefferies
Subscribe for More Information
August 24, 2015
12:01 EDTRHHBYRoche buys nucleic acid purification technology from Lumora
Roche has signed a definitive asset purchase agreement with Lumora for products associated with the patent-protected Heat Elution technology for nucleic acid purification of multiple sample types including challenging formalin-fixed paraffin-embedded tumor samples. Roche plans to explore integrating this technology into its sequencing workflow solution.
08:31 EDTHALOHalozyme names Michael LaBarre chief scientific officer
Halozyme named Michael J. LaBarre, Ph.D. as chief scientific officer, succeeding Dr. Michael Shepard, who was appointed a Research Fellow for the company. "Mike has deep experience characterizing early stage assets, making him an ideal leader for our research organization as we invest further in our promising pipeline," said Dr. Helen Torley, president and chief executive officer. "We have a full agenda for the second half of 2015 as we broaden the study of our investigational new drug PEGPH20 in multiple tumor types and prepare for our pivotal phase 3 study in pancreatic cancer patients. I am pleased to have a proven leader of Mike's caliber to guide our research efforts as we invest for future growth."
August 23, 2015
12:35 EDTRHHBYBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
09:38 EDTRHHBYUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use